Levitra (Vardenafil, BAY38-9456) + Placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Sexual Dysfunction
Conditions
Sexual Dysfunction, Male Erectile Dysfunction
Trial Timeline
Jul 1, 2006 โ Aug 1, 2007
NCT ID
NCT00377793About Levitra (Vardenafil, BAY38-9456) + Placebo
Levitra (Vardenafil, BAY38-9456) + Placebo is a approved stage product being developed by Bayer for Sexual Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00377793. Target conditions include Sexual Dysfunction, Male Erectile Dysfunction.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00666809 | Phase 2 | Completed |
| NCT00377793 | Approved | Completed |
| NCT00663845 | Approved | Completed |
| NCT00657839 | Phase 2 | Completed |
| NCT00667979 | Approved | Completed |
| NCT00663728 | Approved | Completed |
| NCT00665054 | Approved | Completed |
| NCT00668096 | Approved | Completed |
| NCT00682019 | Phase 3 | Completed |
| NCT00657033 | Phase 3 | Completed |
| NCT00661297 | Phase 3 | Completed |
| NCT00665496 | Phase 3 | Completed |
| NCT00658177 | Phase 3 | Completed |
| NCT00661115 | Phase 3 | Completed |
| NCT00661596 | Phase 3 | Completed |
| NCT00661700 | Phase 3 | Completed |
| NCT00668005 | Phase 3 | Completed |
| NCT00660998 | Approved | Completed |
| NCT00661219 | Phase 3 | Completed |
| NCT00656188 | Phase 2/3 | Completed |
Competing Products
18 competing products in Sexual Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dapoxetine | Johnson & Johnson | Phase 3 | 77 |
| Gardasil Vaccine | Merck | Pre-clinical | 23 |
| sildenafil | Pfizer | Approved | 84 |
| sildenafil | Pfizer | Phase 2 | 51 |
| CP-866,087 + CP-866,087 + CP-866,087 + Placebo | Pfizer | Phase 2 | 51 |
| PF-00446687 + Placebo | Pfizer | Phase 2 | 51 |
| Bremelanotide | Pfizer | Phase 2 | 51 |
| Sildenafil 100 mg + Placebo | Pfizer | Phase 2 | 51 |
| Alfuzosin | Sanofi | Approved | 84 |
| AVANAFIL + placebo | Sanofi | Phase 3 | 76 |
| Placebo + 0.5 mgTestosterone + 10 mg Buspirone | Brain Biotech | Phase 2 | 44 |
| Placebo + Testosterone + Buspirone hydrochloride | Brain Biotech | Phase 2 | 44 |
| Placebo + Sildenafil + Testosterone | Brain Biotech | Phase 2 | 44 |
| tibolone + estradiol-norethisterone | Organon | Phase 3 | 72 |
| Bremelanotide + Placebo | Palatin Technologies | Phase 3 | 69 |
| bremelanotide | Palatin Technologies | Phase 2 | 44 |
| Bremelanotide | Palatin Technologies | Phase 3 | 69 |
| EVO100 + Placebo | Evofem Biosciences | Phase 3 | 69 |